Parkinson’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
- Published Date : April 15, 2026
- Updated On : June 19, 2026
- Pages : 154
Parkinson’s Disease Market Outlook
Thelansis’s “Parkinson’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Parkinson’s Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Parkinson’s Disease Overview
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of misfolded alpha-synuclein into Lewy bodies. This pathology disrupts basal ganglia motor loops, causing bradykinesia, resting tremor, rigidity, and postural instability. Genetic risk leans heavily on GBA1 and LRRK2 variants, alongside rare familial SNCA, PARK2, or PINK1 mutations. Non-motor symptoms—such as hyposmia, REM sleep behavior disorder, and depression—frequently emerge years before motor deficits, indicating early systemic pathology. While diagnosis remains clinical, it is validated by DaTscan imaging and molecular alpha-synuclein seed amplification assays (alpha-Syn-SAA). Levodopa is the symptomatic gold standard, though long-term exposure induces motor fluctuations and dyskinesia. Advanced motor complications are managed surgically via deep brain stimulation (DBS) or through continuous delivery systems like Vyalev (foslevodopa-foscarbidopa), an approved continuous subcutaneous infusion that drastically limits off-time. However, true disease modification remains a high hurdle; while anti-alpha-synuclein monoclonal antibodies like Roche’s prasinezumab recently demonstrated long-term functional benefits in specialized modeling, they continue to face complex hurdles in late-stage efficacy trials.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Parkinson’s Disease Market Outlook
Thelansis’s “Parkinson’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Parkinson’s Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Parkinson’s Disease Overview
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of misfolded alpha-synuclein into Lewy bodies. This pathology disrupts basal ganglia motor loops, causing bradykinesia, resting tremor, rigidity, and postural instability. Genetic risk leans heavily on GBA1 and LRRK2 variants, alongside rare familial SNCA, PARK2, or PINK1 mutations. Non-motor symptoms—such as hyposmia, REM sleep behavior disorder, and depression—frequently emerge years before motor deficits, indicating early systemic pathology. While diagnosis remains clinical, it is validated by DaTscan imaging and molecular alpha-synuclein seed amplification assays (alpha-Syn-SAA). Levodopa is the symptomatic gold standard, though long-term exposure induces motor fluctuations and dyskinesia. Advanced motor complications are managed surgically via deep brain stimulation (DBS) or through continuous delivery systems like Vyalev (foslevodopa-foscarbidopa), an approved continuous subcutaneous infusion that drastically limits off-time. However, true disease modification remains a high hurdle; while anti-alpha-synuclein monoclonal antibodies like Roche’s prasinezumab recently demonstrated long-term functional benefits in specialized modeling, they continue to face complex hurdles in late-stage efficacy trials.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)